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Brachial-Ankle Pulse Wave Velocity Versus Its Stiffness Index
b-Transformed Value as Risk Marker for Cardiovascular Disease
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Background-—The difference in the predictive ability of the brachial-ankle pulse wave velocity (baPWV) and its stiffness index b-
transformed value (b-baPWV, ie, baPWV adjusted for the pulse pressure) for the development of pathophysiological abnormalities
related to cardiovascular disease or future occurrence of cardiovascular disease was examined.
Methods and Results-—In study 1, a 7-year prospective observational study in cohorts of 3274 men and 3490 men, the area under
the curve in the receiver operator characteristic curve analysis was higher for baPWV than for b-baPWV for predicting the
development of hypertension (0.73, 95% CI=0.70 to 0.75 versus 0.59, 95% CI=0.56 to 0.62; P<0.01) and/or the development of
retinopathy (0.78, 95% CI=0.73 to 0.82 versus 0.66, 95% CI=0.60 to 0.71; P<0.01) by the end of the study period. During study 2,
a 3-year observation period on 511 patients with coronary artery disease, 72 cardiovascular events were conﬁrmed. The C
statistics of both markers for predicting the development of cardiovascular events were similar.
Conclusions-—Stiffness index b transformation of the baPWV may attenuate the signiﬁcance of the baPWV as a risk marker for
development of pathophysiological abnormalities related to cardiovascular disease in male subjects. ( J Am Heart Assoc. 2019;8:
e013004. DOI: 10.1161/JAHA.119.013004.)
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A rterial stiffness is a marker of atherosclerotic vasculardamage and is also an independent predictor of
development of risk of cardiovascular disease (CVD) and also
of future cardiovascular events.1 Stiffening of arteries is
related not only to structural factors, such as atherosclerotic
vascular damage, but also to functional factors, such as the
blood pressure (BP).1 The pulse wave velocity (PWV) is
commonly used as a marker of segmental arterial stiffness. In
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addition, stiffness index b has also been used as a marker of
regional arterial stiffness in several studies, and this marker
has been reported to be a useful predictor of the development
of hypertension or stroke.2-4 PWV is calculated as the
distance between the points of detection of the pulse wave
divided by the time taken for transmission of the pulse wave
between the 2 points, and stiffness index b is calculated as
the difference of the arterial diameter between diastole and
systole divided by the pulse pressure.1-4 Mathematically, in
contrast to PWV, stiffness index b is less inﬂuenced by the
BP.5 Thus, 1 of the limitations of using the PWV is that it is
highly dependent on the operational mean BP,6 and it has
been suggested that interpretation of the arterial stiffness
based on the PWV may be limited by the nonlinear pressure-
elastic behavior of the arteries.7
Although adjustment of the PWV for the mean BP has been
proposed as an approach to overcome this limitation,8 this
approach has not yet been fully accepted in clinical practice.
Recently, a marker determined by stiffness index b transfor-
mation of the PWV, namely the cardio-ankle vascular index
(CAVI) (ie, the heart-ankle PWV adjusted for the pulse
pressure), has been used not only in Asian countries but also
in many other countries (ie, European countries and the
United States).9-13 This index is less inﬂuenced by the BP as
compared with the PWV.9 An aggravated-data meta-analysis
revealed that this parameter is an independent predictor of
the future development of cardiovascular events.13 If one
were to consider the concept of the nonlinear pressure-elastic
behavior of the arteries in the risk assessment for CVD by
measurement of the PWV to measure the arterial stiffness,
then stiffness index b–transformed PWV could perhaps
improve the reliability of the PWV as a risk marker for the
development of CVD. On the other hand, if one were to
consider that arterial stiffness derived from functional factors
additionally affects the risk assessment for CVD, then PWV
without stiffness index b transformation might be a better
predictor of the development of CVD.
In addition to the carotid-femoral PWV, a conventionally
used marker,1,14 especially in Asian countries, measurement
of the brachial-ankle PWV (baPWV) has also been shown to be
a useful risk marker for the development of hypertension,
chronic kidney disease, and future cardiovascular events.1,15-
17 The present study was conducted to examine the difference
in the predictive ability of the baPWV and its stiffness index
b–transformed value (b-baPWV) for future occurrence of
CVD.12 In the same study cohorts as those included in our
previous studies,15,16,18 we examined whether the b-baPWV
had a better or worse predictive ability than the baPWV value
for the development of pathophysiological abnormalities
related to the risk of development of CVD or future
cardiovascular events.
Methods
Data Sharing
The data, analytical methods, and study materials will not be
made available to other researchers for the purpose of
reproducing the results or replicating the procedure.
Design and Subjects
The present study was conducted in 2 cohorts: the ﬁrst
comprised employees working at the headquarters of a single
large Japanese construction company, in which the associa-
tion of the arterial stiffness with the development of
hypertension or organ damage was examined15,16; the other
was a cohort of patients with coronary artery disease (CAD),
who were the subjects of a multicenter prospective observa-
tional study, in whom the association of the arterial stiffness
with the future development of cardiovascular events was
examined.17 The ﬁndings of these studies have already been
reported elsewhere.15-17
Design and Subjects Included for Evaluation of
Hypertension Development or Subclinical Organ
Damage
According to the Occupational Health and Safety Law in
Japan, it is mandatory for all company employees to undergo
annual health checkups. For employees working at the
Clinical Perspective
What Is New?
• Stiffness index b transformation of the brachial-ankle pulse
wave velocity attenuated the predictive value of brachial-
ankle pulse wave velocity for the development of patho-
physiological abnormalities related to the development of
cardiovascular disease (ie, hypertension and retinopathy).
What Are the Clinical Implications?
• Based on the evidence available at present, adjustment of
brachial-ankle pulse wave velocity for the blood pressure to
predict the development of pathophysiological abnormali-
ties related to the development of cardiovascular disease
(ie, hypertension and retinopathy) may have no merit as
compared with using the absolute value of the brachial-
ankle pulse wave velocity.
• Further studies are needed to clarify whether the blood
pressure–adjusted pulse wave velocity is a better predictor
than the unadjusted pulse wave velocity of the risk of
development of cardiovascular disease.
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headquarters of a single large Japanese construction company
located in downtown Tokyo, the baPWV is also measured
annually. Informed consent was obtained from all the study
participants before their participation in this study. The study
was conducted with the approval of the Ethical Guidelines
Committee of Tokyo Medical University (No. 209 and No. 210
in 2003).
We conducted our present study on the basis of the health
checkup data of the subjects obtained for the years 2007 to
2015. The details are reported elsewhere.15 Of a total of 5857
subjects who were working at the headquarters of the
company, subjects who fulﬁlled at least 1 of the following
exclusion criteria were excluded: measurement of the baPWV
conducted only once during the study period, unreliable
accuracy of the measured baPWV (ankle/brachial systolic BP
index <0.95 and/or presence of atrial ﬁbrillation), current
history of hemodialysis, heart disease, and/or cerebrovascu-
lar disease. The total study period was 8 years, but some of
the subjects were withdrawn from the study because of
transfer from the company headquarters to branch ofﬁces,
layoffs, retirement, and so forth (ie, the study period was
shorter in those subjects). Therefore, the mean study period
was determined to be 6.4 years.
Of the remaining 4689 subjects, the data on the 3274 men
who were not taking any antihypertensive medication and
whose BP was categorized as being in the normal range (ie,
<140/90 mm Hg) at the start of the study period were
included in the analysis of the risk factors for the develop-
ment of hypertension (Figure 1).15 In addition, the data on the
remaining 3490 men without proteinuria or retinopathy in
whom the estimated glomerular ﬁltration rate was ≥60 mL/
min per 1.73 m2 at the study baseline were included in the
analysis of the risk factors for the development of renal
damage and retinopathy (Figure 1).
Design and Subjects Included for Evaluation of
Prognosis of Coronary Artery Disease
The present 3-year study (May 2010 to September 2012) was
conducted as part of a previously reported prospective
multicenter observational cohort study, which was conducted
with the participation of 22 university hospitals and afﬁliated
clinics in Japan, to examine the usefulness of vascular
function tests (ie, to assess endothelial function or arterial
stiffness) in the management of Japanese patients with CAD.
The details are reported elsewhere.18,19 The original study
was conducted in subjects whose ﬂow-mediated vasodilata-
tion data were available, but the present study was conducted
in subjects whose baPWV data were available, regardless of
the availability of the data on ﬂow-mediated vasodilatation.
Patients with ankle/brachial systolic BP index values of <0.90
were excluded (Figure 1). The ethical guidelines committees
of the participating institutions approved the study protocol.
Informed consent for participation in the study was obtained
from all subjects. The protocol is registered in the University
Hospital Medical Information Network Clinical Trials Registry
(UMIN000012950).
Study Outcomes
In the present study we assessed 4 outcomes (ie, new onset
of hypertension, decline of the estimated glomerular ﬁltration
rate to <60 mL/min per 1.73 m2 [eGFR <60] or new onset of
proteinuria or ≥15% decrease of the eGFR from the baseline
to the end of the study period, new onset of retinopathy, and
development of cardiovascular events during the study
period); these outcomes were deﬁned as follows:
1. Hypertension: systolic BP (SBP) ≥140 mm Hg and/or
diastolic BP (DBP) ≥90 mm Hg and/or a history of the
subject receiving antihypertensive drug therapy at the time
of the annual health checkups.
2. eGFR: the eGFR was estimated by the Chronic Kidney
Disease Epidemiology Collaboration equation.20
3. Proteinuria: urinary dipstick test result ≥1+(urinary protein
concentration ≥30 mg/dL).16
4. Retinopathy: Based on fundus photographs, hypertensive
(H stage H0, H1, H2, H3, H4) and arteriosclerotic (S: S0,
S1, S2, S3) changes of both fundi evaluated according to
the Scheie classiﬁcation. Then, retinopathy was deﬁned as
the presence of any abnormal changes (H1-4, or S1-3),
that is, the presence of either hypertensive or arterioscle-
rotic changes.
5. Cardiovascular events: A composite of coronary events
(fatal or nonfatal myocardial infarction, coronary artery
restenosis, and de novo coronary artery stenosis as
conﬁrmed by diagnostic imaging), stroke, heart failure, or
sudden death were deﬁned as cardiovascular events. The
details are described elsewhere.18 All cardiovascular
events were reported annually by each institution to the
Efﬁcacy Endpoint Review Committee. The Committee,
consisting of members blinded to information about the
patients, assessed the appropriateness of the clinical
judgment of the cardiovascular events according to
prespeciﬁed criteria.
BP Measurements
Brachial BP was measured as the mean of 2 measurements
obtained in an ofﬁce setting by the conventional cuff method
using a mercury sphygmomanometer. These measurements
were conducted by well-trained nurses. Both measurements
were performed on the same occasion with the subjects in a
seated position after they had rested for at least 5 minutes.
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Measurement of baPWV and Calculation of
BP-Adjusted baPWV
The baPWV was measured using a volume-plethysmographic
apparatus (Form/ABI, Omron Healthcare Co, Ltd, Kyoto,
Japan), as previously described.15-17,21 Brieﬂy, occlusion cuffs
connected to both the plethysmographic and oscillometric
sensors were tied around both the upper arms and above the
ankles of subjects lying in the supine position. The brachial
and posttibial arterial pressures were measured by an
oscillometric sensor. Measurements were conducted after
the subjects had rested for at least 5 minutes in the supine
position in an air-conditioned room (maintained at 24°C)
designated exclusively for this study. The duration of sampling
of the pressure waveform was 10 seconds.
Recently, amethod tocalculate theBP-adjustedPWV (ie, CAVI)
has been partially developed.12 The stiffness index b-transformed
baPWV was calculated using the following formulas12:
Stiffness index b-transformed baPWV (b-baPWV)
¼ lnðSBPpwv=DBPpwvÞ  2:1=ðSBPpwv  DBPpwvÞ
 ðbaPWV represented as m=secÞ2
SBPpwv and DBPpwv = Systolic and diastolic blood pressures
measured at the time of measurement of the baPWV.
Fundus Findings
At the ﬁrst health checkup (baseline), nonmydriatic macula-
centered fundus photographs of the posterior pole were taken
using a fundus camera (AFC-330; Nihon Koden Co, Ltd, Tokyo,
Japan). All photographs were evaluated in a blinded manner by
professional ophthalmologists.
Laboratory Measurements and eGFR
Serum concentrations of triglyceride, total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein
cholesterol, and creatinine, as well as the plasma glucose
concentrations and glycohemoglobin A1c levels were mea-
sured using standard enzymatic methods.
All blood samples were obtained in the morning after the
patients had fasted overnight.
Diabetes Mellitus and Metabolic Syndrome
Diabetes mellitus was deﬁned as a blood glycohemoglobin
level of ≥6.5% and/or patient under medication for diabetes
mellitus. We adopted the modiﬁed criteria of the Japanese
Expert Committee on the Diagnosis and Classiﬁcation of
Metabolic Syndrome for the clinical diagnosis of metabolic
syndrome22; namely, central obesity (body mass index >25),
plus at least 2 of the following 3 criteria: dyslipidemia
(hypertriglyceridemia ≥1.70 mmol/L and/or high-density
lipoprotein cholesterol<1.03 mmol/L), elevated BP (≥130/
85 mm Hg), and elevated plasma glucose (≥6.11 mmol/L).
Statistical Analyses
Data are expressed as meansSD unless otherwise indi-
cated. For assessment of the differences in a variable
between 2 groups, the t test was applied. To examine the
discrimination ability for the binary outcomes, we plotted
receiver-operating characteristic (ROC) curves, and the areas
under the curves (AUCs) in the ROC curve analyses were
compared. For censored survival data, the discrimination was
evaluated by Harrell c-statistics, accounting for censoring.
Although this evaluation was fundamentally based on data
obtained from annual health checkups, some subjects
skipped the annual health checkups conducted at the
company headquarters. Therefore, the mean duration of
follow-up was 6.44 years for the development of hyperten-
sion (n=3274) and 6.42 years for the development of
subclinical organ damage (n=3490), and the mean number
of times that the variables were measured was 5.24 in the
former and 5.22 in the latter category. Thus, because the
times to events were not determined for these outcomes,
logistic regression analyses using a forward selection method
were applied to determine the associations of the baPWV and
b-baPWV measured at the start of the study period with the
outcomes. On the other hand, the associations of the baPWV
and b-baPWV at the start of the study period with the
development of cardiovascular events during the study period
were also assessed by the Cox proportional-hazard regression
models using a forward selection method, in which the cohort
effect was adjusted for as a ﬁxed effect by taking each cohort
as a strata variable. The proportional-hazard assumption was
explored through the log-negative-log of survival function
versus the log of time, and there was no evidence that the
proportional-hazard assumption was violated for either
baPWV or b-baPWV. The baPWV was closely correlated with
the b-baPWV (R=0.94, P<0.01), and, therefore, to avoid the
effect of multiple colinearities, we did not enter the baPWV
and b-baPWV simultaneously in the same model of logistic
regression analysis or the same Cox proportional-hazards
regression analysis model.
Covariates adjusted for in model A included the age, body
mass index, current smoking history, current daily alcohol
intake, mean BP, heart rate, serum levels of low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
triglycerides, uric acid, creatinine, history of medication use
for dyslipidemia, hypertension, and/or hyperuricemia (for
each category: not receiving medication=0, receiving medi-
cation=1), and diabetes mellitus (absence of diabetes melli-
tus=0, and its presence=1). Covariates adjusted for in model
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B included the age, current smoking history, current daily
alcohol intake, heart rate, serum levels of low-density
lipoprotein cholesterol, uric acid, and creatinine, history of
medication use for dyslipidemia and/or hyperuricemia (for
each category: not receiving medication=0, receiving medi-
cation=1), and metabolic syndrome (absence of metabolic
syndrome=0, and its presence=1). Covariates adjusted for in
model C included the age, sex, body mass index, mean BP,
smoking history, left ventricular ejection fraction, serum level
of brain natriuretic peptide, and history of medication use for
hypertension, dyslipidemia, and/or diabetes mellitus, as
reported previously.13 Model A and model B were applied
for identifying predictors of new onset of hypertension (in this
case, the family history of hypertension was added as an
additional covariate), decline of eGFR to <60 or new onset of
proteinuria, ≥15% decrease of the eGFR from the baseline to
the end of the study period, and new onset of retinopathy, and
model C for identifying predictors of the development of
cardiovascular events.
The analyses were conducted using SPSS software
(version 25.0; IBM/SPSS Inc, Armonk, NY) and Stata software
(release 13; StataCorp, College Station, TX). Comparisons of
the AUCs in the ROC curve analyses were conducted using
JMP Pro 12 software (SAS, Cary, NC); P<0.05 was considered
as denoting statistical signiﬁcance in all of the statistical
tests.
Results
Table 1 shows the clinical characteristics of the study
subjects at the start of study period in each of the study
cohorts. The baPWV and BP-adjusted baPWV were higher in
the subjects with CAD than in the subjects without CAD who
were included for examination of the development of hyper-
tension, and they were also higher than in those who were
included for examination of subclinical organ damage by the
end of the study period.
Results of ROC Curve Analyses
Among the study subjects who did not have hypertension at
the start of the study period (n=3274), 474 (14.5%)
developed hypertension during the study period, as we
reported in our previous report.15 The AUCs in the ROC
curve analyses are summarized in Figure 2. The AUC of the
baPWV was 0.73 (95% CI=0.70-0.75), and the values for the
b-baPWV and the variable obtained by dividing the baPWV by
the mean BP were 0.59 (0.56-0.62) and 0.50 (0.47-0.53),
respectively. The AUC of the baPWV for predicting the
development of hypertension was signiﬁcantly larger than
that of the b-baPWV (difference in AUC=0.14, 95% CI=0.13-
0.15, P<0.01). The BP and age may exert an inﬂuence on
the association of the arterial stiffness with the risk of
Figure 1. Flow diagram of subject enrollment in the study. FMD-J indicates Flow-Mediated Dilation Japan.
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development of hypertension.23,24 When the subjects were
divided into 3 tertiles according to the values of the mean
BP at the start of the study period, the AUC of the baPWV
for predicting the development of hypertension was 0.74
(95% CI=0.65-0.83), and that of the b-baPWV was 0.60 (95%
CI=0.50-0.70). Thus, although their 95% CIs overlapped, the
AUC of the baPWV was signiﬁcantly larger than that of the
b-baPWV (difference=0.14, 95% CI=0.07-0.20, P<0.01).
When the subjects were divided into 3 tertiles according
to the age at the start of the study period, we found that
even in the lowest age tertile (ie, patients aged <37 years
old), the AUC of the baPWV (AUC=0.65, 95% CI=0.58-0.72)
for predicting the development of hypertension was signif-
icantly larger than that of the b-baPWV (AUC=0.48, 95%
CI=0.40-0.55) (P<0.01).
Among the study subjects who did not have renal
damage or retinopathy at the start of the study period
(n=3490), 250 developed proteinuria or decline of the eGFR
to <60 (225 developed proteinuria and 29 showed a
decline of the eGFR to <60), 161 had eGFR decreased by
15, and 91 developed retinopathy during the study period.
The AUCs in the ROC curve analyses are summarized in
Figure 2. The AUC of the baPWV for predicting the
development of retinopathy was signiﬁcantly larger than
that of the b-baPWV (difference in AUC=0.12, 95% CI=0.09-
0.15, P<0.01). On the other hand, the AUCs of the 2
markers for (1) the development of proteinuria, (2) decline
of the eGFR to <60, or (3) ≥15% decrease of the eGFR
from the baseline to the end of the study period were not
signiﬁcantly different (Figure 2).
Among the patients with coronary artery disease (n=511),
72 developed cardiovascular events (sudden death=2,
stroke=4, cardiac events=66) during the study period. There
was no signiﬁcant difference in the C statistics of baPWV and
b-baPWV for predicting the development of cardiovascular
events (difference=0.01, 95% CI=0.01-0.03, P=0.21)
(Table 2).
The baPWV/mean BP showed no discrimination ability for
any of the outcomes (Figure 2 and Table 2).
Results of Logistic Regression Analyses
In the present study we compared the predictive ability of the
baPWV with that of the b-baPWV for the development of
hypertension by logistic regression analysis using a forward
selection method. Both analyses using model A, and model B,
in which family history of hypertension was used as an
additional covariate, revealed a signiﬁcant odds ratio of the
baPWV as well as b-baPWV for the development of hyperten-
sion (Table 3).
Logistic regression analyses using a forward selection
method with adjustments for covariates (model A and model
B) identiﬁed the baPWV, but not b-baPWV, as showing a
signiﬁcant odds ratio for the development of retinopathy,
although neither parameter showed signiﬁcant odds ratios for
any of the renal outcome variables (Table 3).
Results of Analyses Using Cox
Proportional-Hazards Model
Table 4 shows the results of analyses performed using a Cox
proportional-hazards model using a forward selection method
to examine the predictive abilities of the baPWV and b-baPWV
for the development of cardiovascular events. Both baPWV
and b-baPWV showed signiﬁcant hazard ratios for the
development of cardiovascular events (Table 4).
Discussion
The signiﬁcance of the PWV adjusted for BP as a marker of
cardiovascular risk has not yet been fully clariﬁed. Although
several approaches have been proposed for adjustment of the
PWV for BP,5,6,8,12 the present study suggests that simply
dividing the baPWV by the mean BP is not adequate for
cardiovascular risk assessment. The present study demon-
strates that the AUCs of the baPWV were signiﬁcantly larger
than those of the b-baPWV (ie, stiffness index b–transformed
baPWV) for predicting new onset of hypertension and new
onset of retinopathy in healthy Japanese men.
Development of Hypertension
Arterial stiffness contributes to the development of hyperten-
sion, and several prospective studies have reported that both
carotid-femoral PWV and baPWV are predictors of the
development of hypertension. In addition, a recent study
has reported that the stiffness index b-transformed heart-
ankle PWV (ie, CAVI) is also a predictor of the development of
hypertension.25 In the present study the baPWV was found to
be a better marker of the risk of development of hypertension
than the b-baPWV. It is well known that subjects with BP in
the high normal range show a higher rate of development of
hypertension as compared with subjects with BP in the
normal range.23 BP increases the value of the baPWV.
Therefore, it is plausible that the baPWV is a better marker
than the b-baPWV for predicting the development of hyper-
tension. In the present study the mean BP was included as a
covariate, and even in subjects with the mean BP in the
lowest tertile at the start of the study period, the baPWV was
found to be a better predictor of the development of
hypertension. Furthermore, the trajectory for age and arterial
stiffness has been demonstrated,24 but we conﬁrmed our
ﬁndings also in the youngest subjects (<37 years old) in this
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Table 1. Clinical Characteristics of Study Subjects at Start of Study
Parameter
For Assessment of the
Development of Hypertension
For Assessment of
Organ Damage
For Assessment of Prognosis
in Patients With CAD
Number 3274 3490 511
Age, y 429 439 649
Sex, men/women 3274/0 3490/0 432/79
BMI, kg/m2 23.72.9 23.93.0 24.83.6
Smoking (current), % 1055 (32.2) 1111 (31.8) . . .
Hx of smoking, % . . . . . . 337 (68.2)*
Alcohol drinking (current), n (%) 2787 (85.1) 2988 (85.6) 217 (45.4)
Ethanol, g/d 12.210.8 12.710.9 11.118.1
SBP, mm Hg 12010 12313 13017
DBP, mm Hg 728 7510 7511
Heart rate, bpm 679 659 6712
baPWV, m/s 12.41.4 12.81.8 16.42.9
b-baPWV 3.40.7 3.50.8 5.71.9
SBPpwv, mm Hg 12111 12414 12916
DBPpwv, mm Hg 749 7610 789
TC, mmol/L . . . . . . 4.430.81
LDL, mmol/L 3.180.78 3.080.80 . . .
HDL, mmol/L 1.620.40 1.610.40 1.320.34
TG, mmol/L 1.350.95 1.400.99 1.551.05
FPG, mmol/L 5.000.69 5.000.70 6.582.00
HbA1c, % 5.20.5 5.30.5 . . .
UA, lmol/L 36573 36772 34877
Crnn, lmol/L 759 759 7522
eGFR, mL/min per 1.73 m2 . . . 868 . . .
DM, % 81 (2.5) 108 (3.1)
MetS, % 162 (4.9) 277 (7.9)
Prior myocardial infarction, % . . . . . . 254 (49.7)
Prior coronary intervention, % . . . . . . 426 (83.4)
BNP, pg/mL . . . . . . 3660
Ejection fraction, % . . . . . . 6110
Medications
Receiving medication for hypertension, % 0 203 (5.8) 468 (91.6)
Receiving medication for dyslipidemia, % 56 (1.7) 77 (2.2) 474 (92.8)
Receiving medication for diabetes mellitus, % 44 (1.3) 63 (1.8) 153 (29.9)
Receiving medication for hyperuricemia, % 112 (3.4) 138 (4.0) . . .
Alcohol drinking indicates number of current drinkers; baPWV, brachial-ankle pulse wave velocity; b-baPWV, stiffness index b–transformed brachial-ankle pulse wave velocity; BMI, body
mass index; BNP, brain natriuretic peptide; CAD, coronary artery disease; Crnn, serum creatinine; DBP, diastolic blood pressure; DBPpwv, diastolic blood pressure at the time of
measurement of the baPWV; DM, number of subjects with diabetes mellitus; eGFR, estimated glomerular ﬁltration rate by the Chronic Kidney Disease Epidemiology Collaboration equation;
Final, at the end of the observation period; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HDL, serum high-density lipoprotein cholesterol; Hx of smoking, history of
smoking; LDL, serum low-density lipoprotein cholesterol; Medications, number and percentage of subjects receiving medication(s); MetS, number of subjects with metabolic syndrome;
prior myocardial infarction, number of subjects with a past history of myocardial infarction; prior myocardial intervention, number of subjects with a past history of percutaneous coronary
intervention; SBP, systolic blood pressure; SBPpwv, systolic blood pressure at the time of measurement of the baPWV; smoking, number of current smokers; start, at the start of the
observation period; TC, total cholesterol; TG, serum triglyceride; UA, uric acid.
*Data on smoking were not available for 17 subjects.
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study cohort. These ﬁndings appear to lend support to the
view that there is no merit to the current practice of stiffness
b index transformation of the PWV for predicting the
development of hypertension.
Development of Microvascular Damage
Increased arterial stiffness fails to attenuate the pulsatile
energy within the blood vessels generated by cardiac
contraction, which is then propagated to the peripheral
microvasculature, causing microvascular damage.1,26-28 Kario
et al reported the existence of an association between the
stiffness index b-transformed heart-ankle PWV (ie, CAVI) and
the development of retinopathy.25 Our ﬁndings in the present
study have demonstrated the baPWV to be a stronger
predictor of new onset of retinopathy than the b-baPWV.
Thus, these ﬁndings may also underscore the limitation of the
current practice of adjusting PWV for the BP to predict the
progression of pulsatile microvasculopathy.
Our previous 3-year follow-up study demonstrated a
signiﬁcant association of the baPWV with the development
of renal damage.16 However, the present 8-year follow-up
study, failed to conﬁrm the signiﬁcance of that association.
Further studies are needed to clarify whether increased
arterial stiffness is a risk factor for the progression of renal
damage in healthy Japanese subjects.
Figure 2. The areas under the curve in the receiver-operator characteristic curve analysis. baPWV indicates brachial-ankle pulse wave velocity;
b-baPWV, stiffness index b–transformed brachial-ankle pulse wave velocity; dashed line, area under curve of the variable obtained by dividing
the brachial-ankle pulse wave velocity by the mean blood pressure; dashed line, with arrow, the areas under the curve of stiffness index b–
transformed brachial-ankle pulse wave velocity; eGFR <60 or proteinuria, estimated glomerular ﬁltration rate <60 mL/min per 1.73 m2 or
proteinuria; eGFRdec15, ≥15% decrease of eGFR from the baseline to end of study period; solid line with arrow, areas under the curve of the
baPWV.
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Cardiovascular Outcomes
The baPWV has been demonstrated to be an independent
predictor of the prognosis in patients with CAD and also in
those with stroke.18,29,30 In a previously reported study,
although the number of study subjects was relatively small,
the stiffness index b–transformed heart-ankle PWV (ie,
CAVI) was also identiﬁed as a predictor of the prognosis in
patients with CAD.31 In the present study, the C statistics
for the development of cardiovascular events, as also the
hazard ratios for the development of cardiovascular events
per 1 SD, were similar between the baPWV and the b-
baPWV. In addition, the b-baPWV was signiﬁcantly higher in
patients with CAD than in middle-aged healthy Japanese
men. These ﬁndings led us to propose the hypothesis that,
in subjects with increased structural arterial stiffness, the
contribution of functional arterial stiffness to the prognosis
is limited. That is, for the same BP levels, the stress on the
arterial wall might be higher in the case of a rigid artery as
compared with that in the case of a pliant artery because
of the lower buffering effect of the arterial wall against BP
in the former31; therefore, hemodynamic abnormalities
associated with elevated BP 1,26-28 might be observed even
in the normal BP range in the presence of increased
structural arterial stiffness. Further study is needed to
clarify whether functional arterial stiffness is an important
factor contributing to the onset of cardiovascular events in
the absence of increased structural arterial stiffness in the
general population.
Clinical Implications
As discussed above, if the concept of the nonlinear pressure-
elastic behavior of the arteries were to be considered in the
risk assessment for CVD by arterial stiffness determined by
measurement of the PWV, stiffness index b-transformed PWV
could possibly be more reliable as a risk marker for the
development of CVD. However, in the present study, PWV
without stiffness index b transformation was found to be a
better predictor of the development of hypertension and
retinopathy. Thus, the present study was the ﬁrst to suggest
the signiﬁcance of the contribution of BP to increased arterial
stiffness, which is associated with the development of
Table 2. Discrimination Statistics for Cardiovascular Events
Variable C Statistic 95% CI
baPWV 0.58 0.51 to 0.65
b-baPWV 0.57 0.49 to 0.64
baPWV/MBP 0.53 0.45 to 0.60
baPWV vs b-baPWV DC statistic 95% CI
0.01 0.01 to 0.03
P=0.21
baPWV indicates brachial-ankle pulse wave velocity; baPWV/MBP = the variable
obtained by dividing the brachial-ankle pulse wave velocity by the mean blood pressure;
b-baPWV, stiffness index b–transformed brachial-ankle pulse wave velocity; BP, blood
pressure; MBP, mean BP.
Table 3. Results of Logistic Regression Analysis Using
Forward Selection Method to Examine Predictive Values of
baPWV and b-baPWV
Variable and
Adjustments
Odds Ratio
(per 1-SD Increase) 95% CI P Value
For new onset of hypertension
Number of study subjects=3274
Number of subjects with new onset of hypertension=474
Crude
baPWV 2.76 2.43 to 3.14 <0.01
b-baPWV 1.47 1.33 to 1.63 <0.01
Model A+HxHBP
baPWV 1.84 1.58 to 2.13 <0.01
b-baPWV 1.19 1.06 to 1.35 <0.01
Model B+HxHBP
baPWV 2.08 1.80 to 2.42 <0.01
b-baPWV 1.14 1.01 to 1.28 0.03
For new onset of proteinuria or eGFR <60
Number of study subjects=3490
Number of subjects with new onset of proteinuria (225) or
eGFR <60 (29) =total 250
Crude
baPWV 1.14 1.01 to 1.29 0.04
b-baPWV 1.08 0.96 to 1.22 0.20
Model A
baPWV 1.01 0.85 to 1.20 0.92
Model B
baPWV 1.01 0.62 to 1.65 0.97
For eGFRdec15
Number of study subjects=3490
Number of subjects with eGFRdec15=161
Crude
baPWV 1.06 0.91 to 1.25 0.46
b-baPWV 1.02 0.87 to 1.19 0.82
For new onset of retinopathy
Number of study subjects=3490
Number of subjects with new onset of retinopathy=91 in a backward
elimination model
Crude
baPWV 1.98 1.70 to 2.29 <0.01
b-baPWV 1.50 1.29 to 1.74 <0.01
Continued
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pathophysiological abnormalities related to CVD (ie, hyper-
tension and retinopathy). Therefore, in subjects with
increased arterial stiffness, strict BP control could be crucial
for the prevention of CVD.
Limitations
The present study had some limitations: (1) the CAVI is
originally calculated from the heart-ankle PWV.9-13 As shown
in Figure 3, the baPWV showed a close correlation with the
heart-ankle PWV (R=0.92, P<0.01) in our cohort (ie, middle-
aged Japanese men); on the other hand, the correlation
between the baPWV and the carotid-femoral PWV, although
signiﬁcant, was not as strong (R=0.73, P<0.01).32 Therefore,
the contribution of the BP to the arterial stiffness represented
by the carotid-femoral PWV, which is known to inﬂuence the
risk of development of CVD, needs to be clariﬁed. (2) the
equations used to calculate the CAVI were not fully applicable
for calculation of the BP-adjusted baPWV, which was used in
the present study12. (3) the present study, conducted to
assess the risk of development of hypertension and subclin-
ical organ damage, did not include female subjects, and the
BP in most subjects was within the range of “normal BP.”
Therefore, further studies are needed to conﬁrm the present
ﬁndings in women, subjects with hypertension, and subjects
of other ethnicities. (4) For assessment of the risk of
development of cardiovascular events, originally, the FMD-J
(Flow-Mediated Dilation Japan) study was designed to examine
the usefulness of ﬂow-mediated vasodilatation of the brachial
artery to predict the risk of development of cardiovascular
events during the 3-year follow-up period in patients with
coronary artery disease, and the sample size was calculated as
642 subjects.19 However, data on the baPWV were available
only for 511 subjects. Thus, the number of study subjects was
not entirely sufﬁcient for this subanalysis. (5) Although
retinopathy is a predictor of future cardiovascular events,33
there is no clear consensus regarding the classiﬁcation of
retinopathy or whether retinal examination is useful for risk
stratiﬁcation.34 (6) An association has been demonstrated
between arterial stiffness and progression of dementia35;
therefore, the next step is to clarify whether PWV rather than
stiffness index b-transformed PWV is also a better predictor of
the development of dementia.
Conclusions
Adjustment of the PWV value for the BP, based on the stiffness
index b, may attenuate the signiﬁcance of the baPWV as a risk
marker for the development of pathophysiological abnormali-
ties related to CVD (ie, hypertension and retinopathy) in male
subjects. In this study the PWV without stiffness index b
transformation was found to be a better predictor of the
development of these pathophysiological abnormalities.
Sources of Funding
This study was supported by Omron Health Care Company
(Kyoto, Japan), Asahi Calpis Wellness Company (Tokyo, Japan),
Table 3. Continued
Variable and
Adjustments
Odds Ratio
(per 1-SD Increase) 95% CI P Value
Model A
baPWV 1.25 1.03 to 1.52 0.02
b-baPWV . . . . . . 0.23
Model B
baPWV 1.93 1.66 to 2.25 <0.01
b-baPWV . . . . . . 0.09
baPWV indicates brachial-ankle pulse wave velocity; b-baPWV, stiffness index
b–transformed brachial-ankle pulse wave velocity; Crnn, serum creatinine; crude, without
adjustment; eGFR <60, number of subjects with reduction of the estimated glomerular
ﬁltration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration
equation to <60 mL/min per 1.73 m2 by the end of the study period; eGFRdec15, 15%
decrease of eGFR from the baseline to the end of the study period; HDL, high-density
lipoprotein cholesterol; HxHBP, family history of hypertension; LDL, low-density
lipoprotein cholesterol; model A, age, body mass index, current smoking, current daily
alcohol intake, mean blood pressure, heart rate, LDL, HDL, TG, UA, Crnn, diabetes
mellitus (HbA1c>6.5 and/or history of medication for diabetes mellitus), history of
medication for dyslipidemia, hypertension, and/or hyperuricemia; model B, age, current
smoking, current daily alcohol intake, heart rate, LDL, UA, Crnn, medication history for
dyslipidemia and/or hyperuricemia, and metabolic syndrome; TG, serum triglyceride; UA,
uric acid.
Table 4. Results of Analysis by Cox Proportional Hazards
Model Using Forward Selection to Examine Predictive Values
of baPWV and b-Transformed baPWV for Cardiovascular
Events
Variable and Adjustments
Hazard Ratio
(per 1-SD Increase) 95% CI P Value
For cardiovascular events
Number of study subjects=511
Number of subjects with new cardiovascular events=72
(sudden death=2, Stroke=4, cardiac events=66)
Crude
baPWV 1.33 1.07 to 1.66 0.01
b-baPWV 1.31 1.04 to 1.64 0.03
Model C
baPWV 1.40 1.12 to 1.75 <0.01
b-baPWV 1.37 1.09 to 1.73 <0.01
baPWV indicates brachial-ankle pulse wave velocity; b-baPWV, stiffness index
b–transformed brachial-ankle pulse wave velocity; model C, age, sex, body mass index,
mean blood pressure, smoking history, left ventricular ejection fraction, serum level of
brain natriuretic peptide, and history of medication for hypertension, dyslipidemia, and/
or diabetes mellitus (the cohort effect was adjusted for as a ﬁxed effect by taking each
cohort as a strata variable).
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(a study of multicenter assessment on the clinical usefulness
of semiautomatic measurement of ﬂow-mediated vasodilata-
tion of the brachial artery: FMD-J [Flow-Mediated Dilation
Japan] study). The sponsor (Omron Health Care Company)
assisted in the data formatting (ie, the data of the baPWV
stored in the hard disk of the equipment used for measure-
ment of the baPWV was transferred to an Excel ﬁle). Other
than this, the company played no role in the design or
conduct of the study, including data collection, management,
analysis, and interpretation of the data, or in the preparation,
review, or approval of the manuscript.
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